Clinical Trial Update: A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study of epacadostat plus durvalumab in selected advanced solid tumors completed; results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer
• Lung Cancer
• Solid Tumors
• Urothelial Cancer

Drugs mentioned

• Durvalumab (durvalumab)
• Epacadostat (epacadostat)

Snippet

Sponsor: Incyte Corporation | Conditions: Solid Tumors, Head and Neck Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2020-12-29